Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced‐stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high‐risk patients from the ECHELON‐1 study-Reference-Cited by-同舟云学术

Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced‐stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high‐risk patients from the ECHELON‐1 study

Published:2021-02-16 Issue:2 Volume:39 Page:185-195
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Hutchings Martin¹^ORCID,Radford John²^ORCID,Ansell Stephen M.³^ORCID,Illés Árpád⁴^ORCID,Sureda Anna⁵,Connors Joseph M.⁶^ORCID,Sýkorová Alice⁷^ORCID,Shibayama Hirohiko⁸^ORCID,Abramson Jeremy S.⁹^ORCID,Chua Neil S.¹⁰^ORCID,Friedberg Jonathan W.¹¹^ORCID,Kořen Jan¹²,LaCasce Ann Steward¹³^ORCID,Molina Lysiane¹⁴,Engley Gerald¹⁵,Fenton Keenan¹⁵,Jolin Hina¹⁶,Liu Rachael¹⁶^ORCID,Gautam Ashish¹⁶^ORCID,Gallamini Andrea¹⁷^ORCID

Affiliation:

1. Department of Haematology and Phase 1 Unit Rigshospitalet Copenhagen Denmark

2. Manchester Academic Health Science Centre, University of Manchester and the Christie NHS Foundation Trust Manchester UK

3. Mayo Clinic Rochester Minnesota USA

4. Department of Hematology Faculty of Medicine, University of Debrecen Debrecen Hungary

5. Clinical Hematology Department Institut Català d'Oncologia‐Hospitalet and Institut d'Investigacions Biomèdiques de Bellvitge (IDIBELL) Universitat de Barcelona Barcelona Spain

6. Centre for Lymphoid Cancer BC Cancer Vancouver British Columbia Canada

7. University Hospital and Faculty of Medicine Hradec Králové Czech Republic

8. Department of Hematology and Oncology Osaka University Osaka Japan

9. Massachusetts General Hospital Cancer Center Boston Massachusetts USA

10. Cross Cancer Institute University of Alberta Edmonton Alberta Canada

11. Wilmot Cancer Institute University of Rochester Medical Center Rochester New York USA

12. First Faculty of Medicine General University Hospital Prague Czech Republic

13. Dana‐Farber Cancer Institute Boston Massachusetts USA

14. CHU de Grenoble Grenoble France

15. Seattle Genetics Bothell Washington USA

16. Millennium Pharmaceuticals, Inc. Cambridge Massachusetts USA

17. Research and Innovation Department Centre Antoine Lacassagne Nice France